Savine Therapeutics Overview

  • Founded
  • 2007

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Savine Therapeutics General Information

Description

Developer of therapeutics software designed to develop scrambled antigen vaccine (Savine). The company's therapeutics software is used to design antigens which are scrambled or re-engineered from key proteins, enabling doctors and physicians to retain immunologically-relevant characteristics while removing dangerous functions through a vaccine.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Healthcare Technology Systems
Acquirer
Primary Office
  • 15 London Circuit
  • Suite 1, Level 8
  • Canberra, Australian Capital Territory 2600
  • Australia

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Savine Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Savine Therapeutics‘s full profile, request access.

Request a free trial

Savine Therapeutics Patents

Savine Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2006322645-A1 Treatment of epstein-barr virus-associated diseases Inactive 06-Dec-2005
AU-2001259957-A1 Synthetic peptides and uses therefore Active 26-May-2000

Savine Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Ian Ramshaw Co-Founder
Scott Thomspon Co-Founder
To view Savine Therapeutics’s complete executive team members history, request access »